F.H.J. van den Hoogen

25.3k citations

250 papers · 11.1k indexed · 3 hit papers · h-index 49

Rheumatology top 0.05%
Pathology and Forensic Medicine top 0.2%
Immunology top 0.5%
Radiology, Nuclear Medicine and Imaging top 0.5%
Epidemiology top 2%

Co-authors: Walther J. van Venrooij Gerard A. Schellekens L B van de Putte Brigit A. de Jong B.A.W. de Jong Alfons A den Broeder Piet L. C. M. van Riel Ferdinand C. Breedveld
Topics: Systemic Sclerosis and Related Diseases (81 papers)Rheumatoid Arthritis Research and Therapies (66 papers)Systemic Lupus Erythematosus Research (27 papers)
Cited by: Rheumatology Pathology and Forensic Medicine Immunology
Journals: New England Journal of Medicine Cell Journal of Clinical Investigation
Partner nations: Netherlands United States United Kingdom

In The Last Decade

F.H.J. van den Hoogen

244 papers receiving 10.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide

2000 1.1k citations F.H.J. van den Hoogen et al. profile →
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.

1998 1.1k citations F.H.J. van den Hoogen et al. profile →
The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis

2000 509 citations F.H.J. van den Hoogen et al. profile →

Peers

Countries citing papers authored by F.H.J. van den Hoogen

Since Specialization

Citations

This map shows the geographic impact of F.H.J. van den Hoogen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F.H.J. van den Hoogen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F.H.J. van den Hoogen more than expected).

Fields of papers citing papers by F.H.J. van den Hoogen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F.H.J. van den Hoogen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F.H.J. van den Hoogen. The network helps show where F.H.J. van den Hoogen may publish in the future.

Co-authorship network of co-authors of F.H.J. van den Hoogen

This figure shows the co-authorship network connecting the top 25 collaborators of F.H.J. van den Hoogen. A scholar is included among the top collaborators of F.H.J. van den Hoogen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F.H.J. van den Hoogen. F.H.J. van den Hoogen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial 2022 ·Annals of the Rheumatic Diseases ·(unknown),Nathan den Broeder,F.H.J. van den Hoogen,E. Mahler,Steven Teerenstra,Désirée van der Heijde,Lise M Verhoef,Alfons A den Broeder	21
2	Discovery of Psoriatic Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) Study: A Prospective Observational Cohort 2022 ·Acta Dermato Venereologica ·(unknown),(unknown),Mark H. Wenink,Marcel C. Pasch,F.H.J. van den Hoogen,J. M. P. A. van den Reek,E.M.G.J. de Jong	7
3	Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER): Protocol for a Longitudinal Observational Study 2021 ·JMIR Research Protocols ·(unknown),J. M. P. A. van den Reek,Hans Groenewoud,Marcel C. Pasch,F.H.J. van den Hoogen,Mark H. Wenink,E.M.G.J. de Jong	2
4	Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study 2021 ·Lara D. Veeken ·(unknown),Nathan den Broeder,(unknown),F.H.J. van den Hoogen,Lise M Verhoef,Alfons A den Broeder	10
5	Response To: 'Effectiveness of Low-Dose Radiation Therapy on Symptoms in Patients With Knee Osteoarthritis' 2020 ·Annals of the Rheumatic Diseases ·E. Mahler,M.J.M. Minten,(unknown),P Poortmans,J.W.H. Leer,Simone S. Boks,F.H.J. van den Hoogen,Alfons A den Broeder,C.H.M. van den Ende	1
6	Comparison of physical activity among different subsets of patients with knee or hip osteoarthritis and the general population 2020 ·Rheumatology International ·(unknown),(unknown),Jennifer Meessen,W.F. Peter,T. P. M. Vliet Vlieland,(unknown),Job van der Palen,F.H.J. van den Hoogen,C.H.M. van den Ende	7
7	What do patients prefer? A multinational, longitudinal, qualitative study on patient-preferred treatment outcomes in early rheumatoid arthritis 2020 ·RMD Open ·Kristien Van der Elst,Elke Mathijssen,(unknown),Ann Bremander,An De Groef,Elisabet Lindqvist,(unknown),(unknown),F.H.J. van den Hoogen,Yvonne van Eijk‐Hustings,(unknown),Johanna E Vriezekolk,René Westhovens,Ingrid Larsson	12
8	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study 2020 ·Annals of the Rheumatic Diseases ·(unknown),Jeska de Vries‐Bouwstra,C.H.M. van den Ende,(unknown),(unknown),Bram Geurts,Miranda Snoeren,Anne A. Schouffoer,Julia Spierings,Jacob M. van Laar,T. Huizinga,Alexandre E. Voskuyl,Erik W.A. Marijt,Walter J. F. M. van der Velden,F.H.J. van den Hoogen,Madelon C Vonk	40
9	An Electronic Health Tool to Prepare for the First Orthopedic Consultation: Use and Usability Study 2019 ·JMIR Formative Research ·(unknown),T. P. M. Vliet Vlieland,Vincent Busch,Henk Schers,F.H.J. van den Hoogen,C.H.M. van den Ende	6
10	Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis 2018 ·RMD Open ·Lieke Tweehuysen,Nathan den Broeder,Noortje van Herwaarden,Leo A. B. Joosten,P.L. van Lent,Thomas Vogl,F.H.J. van den Hoogen,Rogier M. Thurlings,Alfons A den Broeder	29
11	Emergency front‐of‐neck airway by ENT surgeons and residents: A dutch national survey 2018 ·Laryngoscope Investigative Otolaryngology ·(unknown),(unknown),Gert Jan Scheffer,Monique A. H. Steegers,F.H.J. van den Hoogen	5
12	Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis 2018 ·Patient Preference and Adherence ·Elke Mathijssen,Johanna E Vriezekolk,A M M Eijsbouts,F.H.J. van den Hoogen,Bart J. F. van den Bemt	17
13	Three-year trajectories of disability and fatigue in systemic sclerosis: a cohort study. 2017 ·PubMed ·(unknown),Linda Kwakkenbos,Madelon C Vonk,F.H.J. van den Hoogen,T. P. M. Vliet Vlieland,C.H.M. van den Ende	7
14	Frequency and impact of disease symptoms experienced by patients with systemic sclerosis from five European countries. 2015 ·PubMed ·(unknown),Linda Kwakkenbos,Catarina Leite,Brett D. Thombs,F.H.J. van den Hoogen,Ângela Maia,T. P. M. Vliet Vlieland,C.H.M. van den Ende	26
15	Health care use and patients' perceptions on quality of care in systemic sclerosis. 2013 ·PubMed ·(unknown),Linda Kwakkenbos,Christina Bode,F.H.J. van den Hoogen,C.H.M. van den Ende	17
16	Cross-Language Measurement Equivalence of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis: A Comparison of Canadian and Dutch Patients 2013 ·PLoS ONE ·Linda Kwakkenbos,Erin Arthurs,F.H.J. van den Hoogen,Marie Hudson,W.G.J.M. van Lankveld,Murray Baron,C.H.M. van den Ende,Brett D. Thombs	13
17	Addressing patient health care demands in systemic sclerosis: pre-post assessment of a psycho-educational group programme. 2011 ·PubMed ·Linda Kwakkenbos,(unknown),Madelon C Vonk,(unknown),C.H.M. van den Ende,F.H.J. van den Hoogen,W.G.J.M. van Lankveld	18
18	A large multicenter analysis of CTGF-945 promoter polymorphism does not confirm association with systemic Sclerosis susceptibility or phenotype 2008 ·Lund University Publications (Lund University) ·Blanca Rueda‐Medina,Carmen Pilar Simeón‐Aznar,Roger Hesselstrand,Ariane L. Herrick,Jane Worthington,Norberto Ortego‐Centeno,Gabriela Riemekasten,Vicent Fonollosa,(unknown),F.H.J. van den Hoogen,Julio Sánchez-Román,(unknown),Rosa García-Portales,A. Pros,M T Camps,Miguel Á. González‐Gay,Marieke J. H. Coenen,Nathalie Lambert,J. Lee Nelson,Timothy Radstake,(unknown)	1
19	Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis 2007 ·Annals of the Rheumatic Diseases ·Madelon C Vonk,Zora Marjanovic,F.H.J. van den Hoogen,Sarah Zohar,A Schattenberg,WE Fibbe,(unknown),Éliane Gluckman,Frank Preijers,Arie P.J. van Dijk,J. J. Bax,P. Roblot,P. L. C. M. van Riel,Jacob M. van Laar,Dominique Farge	122
20	Survivorship of the KUDO total elbow prosthesis— comparative study of cemented and uncemented ulnar components: 89 cases followed for an average of 6 years 2007 ·Acta Orthopaedica ·Huub J. L. van der Heide,(unknown),(unknown),Denise Eygendaal,F.H.J. van den Hoogen,M.C. de Waal Malefijt	28

About F.H.J. van den Hoogen

F.H.J. van den Hoogen is a scholar working on Rheumatology, Pathology and Forensic Medicine and Dermatology, having authored 250 papers that have together received 11.1k indexed citations. Recurring topics across this work include Systemic Sclerosis and Related Diseases (81 papers), Rheumatoid Arthritis Research and Therapies (66 papers) and Systemic Lupus Erythematosus Research (27 papers). The work is most often cited by research in Rheumatology (5.2k citations), Pathology and Forensic Medicine (2.9k citations) and Immunology (2.7k citations). F.H.J. van den Hoogen has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Walther J. van Venrooij, Gerard A. Schellekens, L B van de Putte, Brigit A. de Jong, B.A.W. de Jong, Alfons A den Broeder, Piet L. C. M. van Riel, Ferdinand C. Breedveld, Johanna M. W. Hazes and Bart J. F. van den Bemt. Their work appears in journals such as New England Journal of Medicine, Cell and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact